The planned program is part of beta test of Repositive’s Cancer Models platform which connects biopharmaceutical companies and contract research organizations.
After an unsuccessful commercialization attempt more than a decade ago, the company is bringing a revamped version of the ion mobility technology to market.
OmniTier claims that CompStor performs comparably to standard alignment-based methods but may be a more affordable solution for customers with limited budgets.
Israeli firm DNATix recently claimed not only the transfer of a genetic sequence using blockchain technology, but the transfer of a complete Y chromosome.
The Israeli firm recently announced the results of a multicenter study of its Bladder EpiCheck test in addition to netting €2.5 million in EU funding to develop a lung cancer assay.
The firm, which specializes in multiplexed protein analysis, has placed CODEX systems in 10 sites and is planning a broad launch of the platform later this year.
The Dutch multinational is now on track to introduce a kitted version of the assay, which can be run on standard quantitative PCR equipment, by the end of the year.
Backed by Andreessen Horowitz and Polaris Partners, Camp4 hopes its high-resolution gene maps can shorten and remove risk from the drug development process.
PredictImmune's test relies on a 16-marker panel run using quantitative PCR to stratify Crohn's disease and ulcerative colitis patients according to the severity of their illnesses.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
